From database of clinical trials recuiting patients

A plasmacytoma is a discrete, solitary mass of neoplastic monoclonal plasma cells in either bone or soft tissue (extramedullary). Types are as follows: Soft-tissue (extramedullary) plasmacytoma (SEP) Solitary bone plasmacytoma (SBP) Multifocal form of multiple myeloma Multiple myeloma Plasmablastic sarcoma To simplify, solitary plasmacytomas can be divided into 2 groups according to location: Plasmacytoma of the skeletal system (SBP) Soft tissue (extramedullary) plasmacytoma (SEP)

Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma. National Guideline Clearinghouse

Multiple Myeloma and Other Plasma Cell Neoplasms (PDQ®): Treatment
Multiple myeloma is a systemic malignancy of plasma cells that is highly treatable but rarely curable. It is potentially curable when it presents as a solitary plasmacytoma of bone or as an extramedullary plasmacytoma. The median survival in the prechemotherapy era was about 7 months. After the introduction of chemotherapy, prognosis improved significantly with a median survival of 24 to 30 months and a 10-year survival of 3%.

The Doctor's Doctor Plasmacytoma is a localized collection of monoclonal plasma cells. The disease is divided into primary plasmacytoma of the bone and extramedullary plasmacytoma. The importance of the diagnosis rests with the potential for these disorders to progress to multiple myeloma. Solitary plasmacytoma of the bone are usually painful and present with a lytic lesion on radiographs.

Abstract Less than 5% of patients with a plasma cell dyscrasia present with a single bone (SBP) or extramedullary plasmacytoma (EMP) without evidence of systemic disease (normocalcemia, absence of anemia, preservation of uninvolved immunoglobulins, or renal disease attributable to myeloma). Diagnosis requires biopsy confirmation of a monoclonal plasma cell infiltrate from a single site. The treatment of choice for both entities is radiotherapy given with curative intent (> 4000 cGy) resulting in long term disease-free survival in approximately 30% of patients with SBP and 65% of patients with EMP Full text available Hematology 2005 © 2005 The American Society of Hematology

Radiology case 4411-3451

Radiology case 454-3451

solitary plasmacytoma